Biotech | March 11, 2022
First-in-human trial in US for Gan & Lee type 2 diabetes drug
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The product will be manufactured at Lupin’s facility in Goa, India
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
Price was the key driver for the period
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
